Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.

Julie N. Graff,Scott T. Tagawa,Christopher J. Hoimes,Winald R. Gerritsen,Ulka N. Vaishampayan,Tony Elliott,Clara Hwang,A.J. ten Tije,Aurelius Omlin,Raymond S. McDermott,Yves Fradet,Deepak Kilari,Cristiano Ferrario,Hiroji Uemura,Cuizhen Niu,Christian Heinrich Poehlein,Ronald de Wit,Charles Schloss,Johann S. de Bono,Emmanuel S. Antonarakis

Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.

2021

5042Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study to evaluate pembrolizumab (pembro) in mCRPC. A previous analysis of patients with RECIST-measurable (cohort 4 [C4]) or bone-...

Keywords:

Medicine
Internal medicine
castration resistant
Phases of clinical research
Cohort
Oncology
Pembrolizumab
Prostate cancer
Enzalutamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations